Induction chemotherapy administration increases the risk of radiation pneumonitis in unresectable stage III NSCLC patients undergoing concurrent chemoradiotherapy with immunotherapy
Therapeutic Advances in Medical Oncology
Published online on February 20, 2026
Abstract
Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Background:Concurrent chemoradiotherapy (cCRT) is essential for stage III unresectable non-small cell lung cancer (NSCLC) but increases the risk of radiation pneumonitis (RP), especially with immunotherapy (IO). Induction chemotherapy (ICT) controls tumor ...
Background:Concurrent chemoradiotherapy (cCRT) is essential for stage III unresectable non-small cell lung cancer (NSCLC) but increases the risk of radiation pneumonitis (RP), especially with immunotherapy (IO). Induction chemotherapy (ICT) controls tumor ...